Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of darunavir/ritonavir in HIV-1 infected subjects from prior Tibotec trials
2004-001246-33Phase 2Completed
- Sponsor
- Tibotec
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darunavir in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1, sponsored by Tibotec. Primary endpoint: Long-term safety and tolerability of darunavir/ritonavir 600/100 mg twice daily. Started Oct 2004; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2004-001246-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001246-33.